Conferences & Courses
Biomarkers & Diagnostics World Congress Biomarkers & Diagnostics World Congress
May 5-7, 2015 | Philadelphia, PA
The signature event/conference in Cambridge Healthtech Institute' s Biomarker Series, The Biomarker World Congress/conference 2013 is dedicated to all areas of biomarker research spanning the pharmaceutical and diagnostic pipeline.

Biomarkers for Patient Selection Biomarkers for Patient Selection
May 5-6, 2015 | Philadelphia, PA

Cell-Free Biomarkers and Diagnostics Cell-Free Biomarkers and Diagnostics
May 5-6, 2015 | Philadelphia, PA

Life Science Media Library
Next Generation Sequencing as a Diagnostics Platform Next Generation Sequencing as a Diagnostics Platform
August 19, 2014 |
Next generation sequencing (NGS) has revolutionized genomics and is now on the verge of being widely adopted for medical sequencing. Until recently, comprehensive genetic testing for genetically heterogeneous diseases was limited by the high cost of traditional (Sanger) sequencing technology. NGS technologies have now completely eliminated this limit such that virtually any gene with a published association to the disease of interest can be tested. Whole exome or whole genome sequencing (WES/WGS) is the ultimate genetic test and many success stories provide a taste of its power. However, while the cost of generating high-quality whole genome sequence data is rapidly dropping, analysis of the enormous number of variants detected is still too complex to implement WGS/WES as a first line genetic test. Targeted NGS-based gene panels are typically an order of magnitude smaller than WES/WGS based testing but follow the same principles. Screening large sets of genes is particularly useful when the clinical diagnosis is uncertain as it eliminates the need for costly and lengthy cascade testing that has dominated genetic testing in the past. Drawbacks are significantly increased numbers of detected variants, which poses novel challenges for post-analytic data analyses. The focus of this short course is on understanding the use of NGS in clinical diagnosis, practical implementation of NGS in clinical laboratories and analysis of large data sets by using bioinformatics tools to parse and interpret data in relation to the clinical phenotype. The concluding presentation is dedicated to quality and standardization of NGS assays.
Overcoming Challenges of Working with FFPE Samples Overcoming Challenges of Working with FFPE Samples
August 18, 2014 |
The course provides important insights for overcoming challenges of working with FFPE samples for cancer research such as detecting RNA and profiling miRNA expression. Next generation sequencing (NGS) utilizes FFPE samples for clinical retrospective studies. Successful interpretation of the samples depends on the quality of the starting material.
NGS Data Analysis-Determining Clinical Utility of Genome Variants NGS Data Analysis-Determining Clinical Utility of Genome Variants
August 18, 2014 |
Advances in NGS have provided unprecedented opportunities to mine genetic data from individuals to populations. The subsequent identification of genetic variants which may be implicated in disease is an important step in linking sequence data with disease and provides new approaches to improve human health. This course will explore the strategies of genomic data analysis and interpretation, an emergent discipline that seeks to deliver better answers from NGS data so that patients and their physicians can determine informed healthcare decisions.

Publications, Reports, & Whitepapers
Liquid Biopsy: An Emerging Market for Radically Improved Cancer Mgmt
Liquid Biopsy: An Emerging Market for Radically Improved Cancer Management report explores the background, history and basic research of liquid biopsy covering the three sample categories that dominate liquid biopsy today: circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), and extracellular vesicles (EVs, also known as exosomes). This report also details the commercial aspects, market dynamics, and trends of liquid biopsy.